                </a></li></ul></div><p><strong>Figure 2.  <span>Effect of JAK2 V617F on leukocyte and platelet counts.</span></strong></p><a id="article1.body1.sec3.sec2.fig1.caption1.p1" name="article1.body1.sec3.sec2.fig1.caption1.p1"></a><p>(A) Peripheral blood leukocyte counts for the three cohorts in Balb/c and B6 backgrounds as in <a href="#pone-0000018-g001">Figure 1</a>.</p>
<a id="article1.body1.sec3.sec2.fig1.caption1.p2" name="article1.body1.sec3.sec2.fig1.caption1.p2"></a><p>The difference in leukocyte counts between JAK2 V617F and JAK2 WT recipients was significant for the Balb/c cohort (<em>P</em> = 0.0039) but not for B6 (<em>P</em> = 0.0542, unpaired <em>t</em>-test).</p>
<a id="article1.body1.sec3.sec2.fig1.caption1.p3" name="article1.body1.sec3.sec2.fig1.caption1.p3"></a><p>The hatched portion of the histogram represents the percentage of the total leukocyte count comprised by neutrophils.</p>
<a id="article1.body1.sec3.sec2.fig1.caption1.p4" name="article1.body1.sec3.sec2.fig1.caption1.p4"></a><p>(B) Wright-Giemsa-stained cytospins of peripheral blood leukocytes from representative mice with BCR-ABL-induced CML-like MPD (left) or JAK2 V617F-induced PV-like MPD (right).</p>
<a id="article1.body1.sec3.sec2.fig1.caption1.p5" name="article1.body1.sec3.sec2.fig1.caption1.p5"></a><p>Note the predominance of mature neutrophils and lack of immature myeloid elements (myelocytes and promyelocytes) in the JAK2 V617F recipient.</p>
<a id="article1.body1.sec3.sec2.fig1.caption1.p6" name="article1.body1.sec3.sec2.fig1.caption1.p6"></a><p>(C) Platelet counts for the groups in (A).</p>
<a id="article1.body1.sec3.sec2.fig1.caption1.p7" name="article1.body1.sec3.sec2.fig1.caption1.p7"></a><p>There was no significant difference in platelet counts between the three cohorts in either stain.</p>
<a id="article1.body1.sec3.sec2.fig1.caption1.p8" name="article1.body1.sec3.sec2.fig1.caption1.p8"></a><p>(D) GFP fluorescence (left panels) and phase contrast images (right panels) of purified megakaryocytes from recipients of JAK2 V617F-transduced BM (top panels) or normal control mice (bottom panels).</p>
<a id="article1.body1.sec3.sec2.fig1.caption1.p9" name="article1.body1.sec3.sec2.fig1.caption1.p9"></a><p>Note the GFP fluorescence in the majority of megakaryocytes from JAK2 V617F recipients.</p>
<a id="article1.body1.sec3.sec2.fig1.caption1.p10" name="article1.body1.sec3.sec2.fig1.caption1.p10"></a><p>(E) Tail bleeding time (Balb/c cohort) for the three groups.</p>
<a id="article1.body1.sec3.sec2.fig1.caption1.p11" name="article1.body1.sec3.sec2.fig1.caption1.p11"></a><p>The mean bleeding time (bar) of JAK2 V617F recipients was significantly longer than that of vector or JAK2 WT recipients (<em>P</em> = 0.0328 and <em>P</em> = 0.0002, respectively, unpaired <em>t</em>-test).</p>
